The Use of LLLT to Treat Dry Age-Related Macular Degeneration


To build and test a device that may delay progression of the dry form of age-related macular degeneration

Anticipated Impact: 

An easily administered treatment that will slow progression of vision loss in patients with age-related macular degeneration, resulting in improved quality of life and independence


Age-related macular degeneration affects the center of the field of vision, making many ordinary activities difficult, and affects millions of typically elderly people a year. The “dry” form has no treatment. Particular wavelengths of light appear to activate cellular repair mechanisms that significantly delayed progression of disease in a human clinical trial.  A device will be constructed and characterized in preparation for FDA approval.

Collaborating organizations: Product Creation Studio, Uniformed Services University of the Health Sciences

Age-related Macular Degeneration Treatment

Grant Update

Principal Investigator:
Clark Tedford
Grantee Organization:
LumiThera, Inc.
Grant Title:
The Use of LLLT to Treat Dry Age-Related Macular Degeneration
Grant Cohort and Year:
2014 Proof of Concept (03)
Grant Period:
06/01/2014 - 05/31/2015 (Completed)
Grant Amount:
The LSDF grant allowed LumiThera to build a prototype ophthalmologic LT-300 LED instrument. The instrument was successfully completed and tested for light penetration and scatter in the human eye. The completion of the grant provides LumiThera with a novel instrument to treat subjects with dry age-related macular degeneration, and other ocular diseases.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 23, 34, 36, 37, 43, 46

Health Impacts

Age-related Macular Degeneration Treatment